[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201790254A1 - Новые модуляторы рецептора glp-1 - Google Patents

Новые модуляторы рецептора glp-1

Info

Publication number
EA201790254A1
EA201790254A1 EA201790254A EA201790254A EA201790254A1 EA 201790254 A1 EA201790254 A1 EA 201790254A1 EA 201790254 A EA201790254 A EA 201790254A EA 201790254 A EA201790254 A EA 201790254A EA 201790254 A1 EA201790254 A1 EA 201790254A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
receptor modulators
peptide
compounds
receptor
Prior art date
Application number
EA201790254A
Other languages
English (en)
Other versions
EA032525B1 (ru
Inventor
Маркус Ф. Боэм
Эстер Мартинборо
Маниша Мурджани
Дзунко Тамия
Лимин Хуан
Адам Р. Йиджер
Энугуртхи Брахмачари
Томас Фаулер
Эндрю Новак
Премдзи Мегхани
Майкл Нэггз
Original Assignee
Селджин Интернэшнл Ii Сарл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Интернэшнл Ii Сарл filed Critical Селджин Интернэшнл Ii Сарл
Publication of EA201790254A1 publication Critical patent/EA201790254A1/ru
Publication of EA032525B1 publication Critical patent/EA032525B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предложены соединения, которые модулируют рецептор глюкагонподобного пептида 1 (GLP-1), а также способы их синтеза и способы их терапевтического и/или профилактического применения. Такие соединения могут воздействовать в качестве модуляторов или потенциаторов рецептора GLP-1 самостоятельно или с инкретиновыми пептидами, такими как GLP-1(7-36), GLP-1(9-36) и оксинтомодулин, или с основанными на пептидах препаратами, такими как эксенатид и лираглутид, и имеют следующую общую структуру (где "" представляет любую из двух или обе R- и S-формы данного соединения):где А, В, С, R, R, R, R, R, n, p и q являются такими, как определено в описании изобретения.
EA201790254A 2014-07-25 2015-07-24 Модуляторы рецептора glp-1 EA032525B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462028962P 2014-07-25 2014-07-25
US201462090040P 2014-12-10 2014-12-10
US201562161650P 2015-05-14 2015-05-14
PCT/US2015/042114 WO2016015014A1 (en) 2014-07-25 2015-07-24 Novel glp-1 receptor modulators

Publications (2)

Publication Number Publication Date
EA201790254A1 true EA201790254A1 (ru) 2017-07-31
EA032525B1 EA032525B1 (ru) 2019-06-28

Family

ID=53777037

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790254A EA032525B1 (ru) 2014-07-25 2015-07-24 Модуляторы рецептора glp-1

Country Status (14)

Country Link
US (2) US9474755B2 (ru)
EP (1) EP3172199B1 (ru)
JP (2) JP6556237B2 (ru)
KR (1) KR102564946B1 (ru)
CN (2) CN112457301A (ru)
AU (1) AU2015292356B2 (ru)
CA (1) CA2955836C (ru)
EA (1) EA032525B1 (ru)
ES (1) ES2819534T3 (ru)
IL (1) IL249896B (ru)
MX (1) MX2017000972A (ru)
SG (1) SG11201700364PA (ru)
WO (1) WO2016015014A1 (ru)
ZA (1) ZA201700342B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
KR102271179B1 (ko) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
US9474755B2 (en) * 2014-07-25 2016-10-25 Celgene International Ii Sarl GLP-1 receptor modulators
CA2969944A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
HRP20211938T1 (hr) * 2016-09-30 2022-03-18 Receptos Llc Sol dimetilaminoetanola od modulatora receptora glp-1
EP3615524B1 (en) * 2017-04-28 2022-11-09 Receptos Llc Novel glp-1 receptor modulators
US20220193080A1 (en) * 2019-04-11 2022-06-23 University Of The Sciences Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
IL300155A (en) 2020-08-06 2023-03-01 Gasherbrum Bio Inc Heterocyclic GLP-1 agonists
CN112121152B (zh) * 2020-09-25 2021-06-22 南京大学 利司那肽在制备抗肿瘤药物中的应用
CN112898133B (zh) * 2021-01-27 2022-11-15 河北迈尔斯通电子材料有限公司 一种反式酮类中间体的制备方法
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1062206B (it) 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
ES2247676T3 (es) 1997-01-07 2006-03-01 Amylin Pharmaceuticals, Inc. Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia.
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999006437A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
PL193283B1 (pl) 1997-08-22 2007-01-31 Hoffmann La Roche Nowe pochodne N-aroilofenyloalaniny, ich zastosowanie i środek leczniczy
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
HUP0104579A3 (en) 1998-12-07 2002-05-28 Univ Tulane Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
YU57802A (sh) 2000-03-07 2005-07-19 Aventis Pharma Deutschland Gmbh. Substituisani 3-fenil-5-alkoksi-1,3,4-oksidiazol-2-oni i njihova primena za inhibiranje hormon-senzitivne lipaze
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
ATE464299T1 (de) 2002-02-20 2010-04-15 Ajinomoto Kk Neues phenylalaninderivat
EP2803667A1 (en) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Phenylalanine derivatives
US20050192279A1 (en) * 2004-02-10 2005-09-01 Kent Barbay Pyridazinones as antagonists of alpha4 integrins
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2008112938A2 (en) 2007-03-13 2008-09-18 New England Medical Center Hospitals, Inc. Composition and method for the treatment of diseases affected by a peptide receptor
WO2008149382A1 (en) 2007-06-08 2008-12-11 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2009111700A2 (en) * 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN102946882B (zh) * 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
TWI523844B (zh) * 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
CN104080767A (zh) * 2011-12-12 2014-10-01 瑞塞普托斯公司 新的glp-1受体调节剂
KR102271179B1 (ko) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
US9474755B2 (en) * 2014-07-25 2016-10-25 Celgene International Ii Sarl GLP-1 receptor modulators

Also Published As

Publication number Publication date
JP6556237B2 (ja) 2019-08-07
IL249896B (en) 2021-02-28
EP3172199A1 (en) 2017-05-31
US20170216392A1 (en) 2017-08-03
AU2015292356B2 (en) 2020-02-06
US20160038487A1 (en) 2016-02-11
AU2015292356A1 (en) 2017-02-02
CA2955836C (en) 2023-02-14
US9474755B2 (en) 2016-10-25
ES2819534T3 (es) 2021-04-16
US9839664B2 (en) 2017-12-12
WO2016015014A1 (en) 2016-01-28
MX2017000972A (es) 2017-07-27
JP2017526734A (ja) 2017-09-14
KR102564946B1 (ko) 2023-08-08
IL249896A0 (en) 2017-03-30
KR20170040233A (ko) 2017-04-12
EA032525B1 (ru) 2019-06-28
CN112457301A (zh) 2021-03-09
EP3172199B1 (en) 2020-07-01
JP2019142984A (ja) 2019-08-29
CN107074820B (zh) 2021-05-18
CN107074820A (zh) 2017-08-18
SG11201700364PA (en) 2017-02-27
CA2955836A1 (en) 2016-01-28
ZA201700342B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
EA201790254A1 (ru) Новые модуляторы рецептора glp-1
MX370666B (es) Novedosos moduladores del receptor de péptido tipo glucagón 1 (glp-1).
CY1122539T1 (el) Αναλογα γλυκαγονης
WO2020086647A8 (en) Ny-eso-1 t cell receptors and methods of use thereof
EA201892057A1 (ru) Соединения-коагонисты гип и гпп-1
EA201690494A1 (ru) Ацилированные аналоги глюкагона
CO2017004489A2 (es) Polipéptidos fgf-21 modificados
ZA201902053B (en) Pharmaceutical composition
EA201291234A1 (ru) Аналоги глюкагона
WO2013090454A3 (en) Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes
EA201690660A1 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
MX2017007641A (es) Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas.
EA201590294A1 (ru) Аналоги глюкагона
EA201990598A1 (ru) Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы
EA201001801A1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
PL3704143T3 (pl) Chemo-enzymatyczna synteza liraglutydu, semaglutydu i glp-1
WO2011156655A3 (en) Novel glp-1 receptor stabilizers and modulators
EA201991029A1 (ru) Ингибиторы magl
CL2008003660A1 (es) Metodo para obtener un peptido insulinotropico tipo glp-1 mediante la union de fragmentos del mismo ya sea en solucion o en fase solida; y peptidos intermediarios aqui empleados.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201591421A1 (ru) Препараты полипептида фактора ix
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
MX2017007494A (es) Moduladores del receptor de peptido 1 tipo glucagon.
EA202090143A1 (ru) Фармацевтически приемлемые соли полипептидов и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM